Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
14
10
2023
pmc-release:
09
11
2024
medline:
17
11
2023
pubmed:
17
11
2023
entrez:
17
11
2023
Statut:
epublish
Résumé
Provided herein are novel emopamil-binding protein (EBP) inhibitors, pharmaceutical compositions, use of such compounds in treating multiple sclerosis, and processes for preparing such compounds.
Identifiants
pubmed: 37974937
doi: 10.1021/acsmedchemlett.3c00457
pmc: PMC10641912
doi:
Types de publication
Editorial
Langues
eng
Pagination
1501-1502Informations de copyright
Published 2023 by American Chemical Society.
Déclaration de conflit d'intérêts
The author declares no competing financial interest.
Références
Biochem Pharmacol. 2022 Feb;196:114611
pubmed: 34010597
Curr Opin Pharmacol. 2022 Jun;64:102205
pubmed: 35344763
Curr Opin Chem Biol. 2022 Oct;70:102201
pubmed: 36037558
Curr Opin Struct Biol. 2022 Jun;74:102369
pubmed: 35398802
ACS Med Chem Lett. 2023 Sep 06;14(10):1318-1319
pubmed: 37849545